Last month at #SNMMI we debuted our first #RadioDARPin therapeutic (RDT) candidate, MP0712, in co-development with Orano Med. 212Pb-labeled MP0712 is designed to precisely target DLL3-expressing tumor cells and is being developed for small cell lung cancer patients. Learn more about “Our DARPin Approach to Radiopharmaceuticals” in this blog by Daniel Steiner, SVP Research & Technology.
Very happy to share with you how we at Molecular Partners are contributing to the field of radiopharmaceuticals with #RadioDARPins and looking forward to sharing more details in 2024, including new data and plans to the clinic! #MolecularPartners #DARPins #RadioDARPins #radiopharmaceuticals #radioligand #nuclearmedicine #oncology #cancer #radiopharma